Dépôt numérique
RECHERCHER

Exploring the potential of plasma and adipose mesenchymal stem cell-derived extracellular vesicles as novel platforms for neuroinflammation therapy

Silva, Rummenigge Oliveira; Haddad, Mohamed; Counil, Hermine; Zaouter, Charlotte; Patten, Shunmoogum A. ORCID logoORCID: https://orcid.org/0000-0002-2782-3547; Fulop, Tamas et Ramassamy, Charles ORCID logoORCID: https://orcid.org/0000-0002-3252-5878 (2024). Exploring the potential of plasma and adipose mesenchymal stem cell-derived extracellular vesicles as novel platforms for neuroinflammation therapy Journal of Controlled Release , vol. 377 . pp. 880-898. DOI: 10.1016/j.jconrel.2024.11.060.

Ce document n'est pas hébergé sur EspaceINRS.

Résumé


Persistent reactive oxygen species (ROS) and neuroinflammation contribute to the onset and progression of neurodegenerative diseases, underscoring the need for targeted therapeutic strategies to mitigate these effects. Extracellular vesicles (EVs) show promise in drug delivery due to their biocompatibility, ability to cross biological barriers, and and specific interactions with cell and tissue receptors. In this study, we demonstrated that human plasma-derived EVs (pEVs) exhibit higher brain-targeting specificity, while adipose-derived mesenchymal stem cells EVs (ADMSC-EVs) offer regenerative and immunomodulatory properties. We further investigated the potential of these EVs as therapeutic carriers for brain-targeted drug delivery, using Donepezil (DNZ) as the model drug. DNZ, a cholinesterase inhibitor commonly used for Alzheimer's disease (AD), also has neuroprotective and anti-inflammatory properties. The size of EVs used ranged from 50 to 300 nm with a surface charge below -30 mV. Both formulations showed rapid cellular internalization, without toxicity, and the ability to cross the blood-brain barrier (BBB) in a zebrafish model. The have analyzed the anti-inflammatory and antioxidant actions of pEVs-DNZ and ADMSC-EVs-DNZ in the presence of lipopolysaccharide (LPS). ADMSC-EVs significantly reduced the inflammatory mediators released by HMC3 microglial cells while treatment with pEVs-DNZ and ADMSC-EVs-DNZ lowered both phagocytic activity and ROS levels in these cells. In vivo experiments using zebrafish larvae revealed that both EV formulations reduced microglial proliferation and exhibited antioxidant effects. Overall, this study highlights the potential of EVs loaded with DNZ as a novel approach for treating neuroinflammation underlying various neurodegenerative diseases.

Type de document: Article
Mots-clés libres: Adipose mesenchymal stem cell-derived extracellular vesicles; Donepezil; Drug delivery; Neuroinflammation; Plasma-derived extracellular vesicles; Reactive oxygen species
Centre: Centre INRS-Institut Armand Frappier
Date de dépôt: 08 déc. 2024 15:38
Dernière modification: 08 déc. 2024 15:38
URI: https://espace.inrs.ca/id/eprint/16230

Gestion Actions (Identification requise)

Modifier la notice Modifier la notice